For patients with prior HR+HER2- localized breast cancer currently receiving adjuvant endocrine therapy, is there a time period in which you would no longer recommend adding adjuvant abemaciclib?

This is a great question and I hope we eventually have data to guide us. I also do not know how insurers will handle these types of requests. This high-risk ER+ population has a 10-year risk of distant recurrence between 20 to 40% with continued risk of recurrence over 20 years based on the EBCTCG d...

The benefit of adjuvant abemaciclib shown in the monarchE trial was in fact, recently updated (Johnston et al., PMID 41110697) and is showing a sustained reduction in recurrence risk (HR 0.664) compared to HR 0.75 in the initial analysis.

However, the question of delayed therapy and whether the impac...

There is no prospective data on using it over 2 years. I am comfortable recommending it for up to 2 years.